Anthropic enters drug discovery — can AI fix Big Pharma's 12-year failure rate?
anthropic launched internal drug discovery programs for neglected diseases to train its ai, signaling a push into high-stakes biology applications.
anthropic will conduct preclinical research for neglected diseases, citing its nonprofit mission and the need for complex training data to improve its ai models. the announcement accompanied the launch of 'claude science', a tool where a ucsf researcher reportedly used claude to identify a year-old viral contamination in minutes. this strategy aligns with broader industry efforts, such as google's isomorphic labs, to cut drug development timelines from 12 to 8 years.